巴曲酶灌注联合TACE/TAI抑制肿瘤生长和转移的初步研究  

A preliminary study on inhibiting growth and metastasis of tumor by transcatheter arterial perfusion of batroxobin combined with TACE/TAI

作　　者：高天俊[1] 许美丽[1] 娄明武[1] 王徽[2] 范义[1] 

机构地区：[1]深圳市龙岗中心医院介入影像科,广东518116 [2]吉林省肿瘤医院介入治疗科,吉林130012

出　　处：《当代医学》2011年第30期34-37,共4页Contemporary Medicine

基　　金：广东省科技研发基金资助项目(73128)

摘　　要：目的探讨临床应用巴曲酶治疗肿瘤的疗效和安全性,以及巴曲酶灌注联合TACE/TAI的治疗优势。方法把40例肝癌及肺癌患者随机分为两组,每组20例。试验组进行巴曲酶灌注联合TACE/TAI治疗,对照组只进行TACE/TAI治疗。然后对两组进行追踪观察,记录结果并进行对比分析。结果 (1)与对照组相比,试验组在治疗后第1个月内血浆纤维蛋白原(FIB)值下降较明显,两组间差异有统计学意义(P<0.05)。(2)治疗后两组瘤体均有缩小,各时段对应相比差异有统计学意义(P<0.05)且"V试验组<V对照组"。(3)两组半年的转移发生率均为5.0%(1/20);试验组1年的发生率为10.0%(2/20),对照组为25.0%(5/20),两组相比:试验组<对照组(x2=0.693,P>0.05)。结论巴曲酶可以快速有效地降低肿瘤患者的血浆FIB水平,与TACE/TAI联合应用,协同性强,疗效优于单纯TACE/TAI治疗,可作为一种肿瘤治疗的新方案应用于临床。Objective To explore the therapeutic efficacy and the safety of batroxobin in patients with tumor and the advantages of transcatheter arterial perfusion ofbatroxobin combined with TACE/TAI. Methods Forty patients with liver cancer or lung cancer were randomized into experimental group（transcatheter arterial perfusion of batroxobin combined with TACE/TAI treatment, 20 patients） and control group（TACE/ TAI alone group,20 patients）. The patients were followed up and the data were recorded, compared and analyzed. Results （1） Compared with the control group, the FIB level in the experimental group was significantly decreased at the first month after treatment（P 〈 0.05）. （2） The size of the tumor was reduced in both groups after the treatment. There was a significant difference between the two groups at different time intervals（p 〈 0.05）. （3） The incidence of metastasis were 5.0%（1/20） in both groups at 6 months after treatment, and that after one year was 10.0%（2/20） in the experimental group and 25.0%（5/20） in the control group. Both the groups compared each other： ＂experimental group 〈 control group （x2=0.693, P〉0.05）. Conclusion Batroxobin can rapidly and effectively decrease the FIB level. Therefore it may be used as an effective and safe adjuvant drug for the treatment of tumor. Transcatheter arterial perfusion of batroxobin combined with TACE/TAI therapy has advantages in comparison with TACE/TAI alone. It could be taken as a new therapeutic regimen in the tumor treatment.

关 键 词：巴曲酶 纤维蛋白原 肿瘤 疗效 

分 类 号：R730.5[医药卫生—肿瘤]